[
  {
    "id": "20251017-001249-69555e3a",
    "createdAt": "2025-10-17T00:12:49.407Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:12:46 PM"
    },
    "articles": [
      {
        "id": 642,
        "title": "4-HO-EPT",
        "slug": "4-ho-ept"
      }
    ],
    "markdown": "# 4-HO-EPT · #642\n\n+{\n+  \"title\": \"4-HO-EPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-EPT\",\n+    \"chemical_name\": \"4-Hydroxy-N-ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Eprocin\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-20 mg\",\n+            \"common\": \"30-40 mg\",\n+            \"strong\": \"40-60 mg\",\n+            \"heavy\": \"60+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5-10 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-25 mg\",\n+            \"strong\": \"25-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-7 hours\",\n+            \"onset\": \"30-60 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"smoked\",\n+          \"stages\": {\n+            \"total_duration\": \"1-2 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"15-30 minutes\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-EPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like most psychedelics, it is generally considered self-regulating. There is no evidence of physical dependence potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-EPT is a novel research chemical with very little history of human use before 2016 and almost no scientific research on its pharmacology, metabolism, or toxicity. Unlike more visual tryptamines, it primarily enhances colors with a neon quality rather than producing strong visual distortions. Users report a strong euphoric body high sometimes compared to opiates, with a generally light and positive mindset. Accurate weighing with a precise milligram scale is essential. Individuals with personal or family history of psychotic disorders should avoid use. Higher doses may cause vasoconstriction. Set and setting considerations apply as with all psychedelics.\",\n+    \"subjective_effects\": [\n+      \"Color Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Euphoric Body High\",\n+      \"Increased Music Appreciation\",\n+      \"Conceptual Thinking\",\n+      \"Analysis Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Time Distortion\",\n+      \"Emotion Enhancement\",\n+      \"Sedation\",\n+      \"Memory Suppression\",\n+      \"Thought Loops\",\n+      \"Nausea\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-ho-ept-thread.805165/\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-EPT Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_4HOEPT.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-HO-EPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?id=5770\"\n+      },\n+      {\n+        \"name\": \"PMC: Investigation of the Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-EPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 642\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000922-9ad8186d",
    "createdAt": "2025-10-17T00:09:22.650Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:09:20 PM"
    },
    "articles": [
      {
        "id": 641,
        "title": "4-HO-DiPT",
        "slug": "4-ho-dipt"
      }
    ],
    "markdown": "# 4-HO-DiPT · #641\n\n+{\n+  \"title\": \"4-HO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-ol\",\n+    \"alternative_name\": \"Iprocin; 4-Hydroxy-DiPT; 4-Hydroxy-N,N-diisopropyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; Serotonin reuptake inhibitor (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3 mg\",\n+            \"light\": \"3-10 mg\",\n+            \"common\": \"10-20 mg\",\n+            \"strong\": \"20-30 mg\",\n+            \"heavy\": \"30+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"15-30 minutes\",\n+            \"peak\": \"60-90 minutes (20-30 minutes after onset)\",\n+            \"offset\": \"30-60 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-DiPT is not habit-forming and has minimal psychological dependence potential. Like most psychedelics, it is considered self-regulating, with the desire to use it typically decreasing with regular consumption.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-DiPT is a research chemical with very limited history of human use and no scientific studies on its toxicity. It is noted for its uniquely rapid onset, short duration, narrow dose sensitivity, and high intensity relative to dose. Physical side effects including muscle tremors, leg tremors, bodily malaise, and temperature dysregulation are commonly reported. Set and setting are critical, and harm reduction practices are essential. The substance is unscheduled in most jurisdictions but may be controlled under analogue laws.\",\n+    \"subjective_effects\": [\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Introspective Insights\",\n+      \"Time Distortion\",\n+      \"Increased Music Appreciation\",\n+      \"Enhanced Tactile Sensation\",\n+      \"Sexual Enhancement\",\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Colour Enhancement\",\n+      \"Muscle Tremors\",\n+      \"Nausea\",\n+      \"Pupil Dilation\",\n+      \"Stimulation\",\n+      \"Temperature Dysregulation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, 2C-x, DOx, 5-MeO-xxT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"2.7-4.1 hours (based on prodrug luvesilocin studies)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt.shtml\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT by Alexander Shulgin\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/read.php?domain=tk&id=17\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy 4-HO-DiPT Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-4-ho-dipt-thread.107890/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: 4-HO-DiPT Trip Reports\",\n+        \"reference\": \"https://drugs-forum.com/threads/4-ho-dipt-trip-reports.3095/\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DiPT\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Repke, D. B. et al. (1977). Psilocin analogs synthesis\",\n+        \"reference\": \"Journal of Heterocyclic Chemistry, 14(1), 71-74\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 641\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000655-9eafe3b2",
    "createdAt": "2025-10-17T00:06:55.306Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:06:53 PM"
    },
    "articles": [
      {
        "id": 640,
        "title": "4-HO-DET",
        "slug": "4-ho-det"
      }
    ],
    "markdown": "# 4-HO-DET · #640\n\n+{\n+  \"title\": \"4-HO-DET\",\n+  \"index-category\": \"psychedelic; tryptamine; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-HO-DET\",\n+    \"chemical_name\": \"3-(2-diethylaminoethyl)-1H-indol-4-ol\",\n+    \"alternative_name\": \"Ethocin; CZ-74; 4-Hydroxy-N,N-diethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"20-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"5-7 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"2.5-3.5 hours (with 30-60 minute come up)\",\n+            \"offset\": \"1.5-2 hours\",\n+            \"after_effects\": \"1-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-HO-DET is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating. Limited evidence suggests no significant addiction potential.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, may significantly increase risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\"\n+      ]\n+    },\n+    \"notes\": \"4-HO-DET is a research chemical with very little history of human usage. The toxicity and long-term health effects have not been studied in any scientific context. It is strongly recommended to use harm reduction practices when using this substance. Legal status varies by jurisdiction; it is unscheduled in the United States but may be prosecuted under the Federal Analogue Act. It is controlled in Germany, Sweden, Switzerland, and the United Kingdom.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Colour Enhancement\",\n+      \"Tactile Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Analysis Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Memory Suppression\",\n+      \"Excessive Yawning\",\n+      \"Temperature Regulation Suppression\",\n+      \"Pupil Dilation\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight 4-HO-DET Discussion Thread\",\n+        \"reference\": \"http://www.bluelight.org/vb/threads/480200-The-Big-amp-Dandy-4-HO-DET-Thread\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-HO-DET Experience Vaults\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_4HODET.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design TiHKAL Entry #16: 4-HO-DET\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5016\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-HO-DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-HO-DET\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: 4-HO-DET\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/4-HO-DET\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 640\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251017-000420-1266ad24",
    "createdAt": "2025-10-17T00:04:20.477Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 6:04:18 PM"
    },
    "articles": [
      {
        "id": 639,
        "title": "4-AcO-MiPT",
        "slug": "4-aco-mipt"
      }
    ],
    "markdown": "# 4-AcO-MiPT · #639\n\n+{\n+  \"title\": \"4-AcO-MiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-AcO-MiPT\",\n+    \"chemical_name\": \"4-Acetoxy-N-methyl-N-isopropyltryptamine\",\n+    \"alternative_name\": \"Mipracetin; O-Acetylmiprocin; 4-Acetoxy-MiPT\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"5 mg\",\n+            \"light\": \"10-15 mg\",\n+            \"common\": \"15-20 mg\",\n+            \"strong\": \"20-35 mg\",\n+            \"heavy\": \"35+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-8 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"1.5-3 hours (come up 1-2 hours)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-AcO-MiPT is not habit-forming and demonstrates a self-regulating pattern typical of psychedelics. The desire to use it tends to decrease with regular consumption rather than increase.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy, may significantly intensify effects)\"\n+      ]\n+    },\n+    \"notes\": \"4-AcO-MiPT is a synthetic psychedelic tryptamine that remains relatively uncommon with limited history of human use. The substance is hygroscopic and degrades quickly when exposed to moisture or improper storage; it should be kept in an inert atmosphere in a freezer. The material can develop a sticky, goop-like consistency when exposed to air. Accurate weighing with a precise milligram scale is essential, as the substance is potent and can appear deceptively small. It is theorized to act as a prodrug for 4-HO-MiPT, though debate continues about whether it possesses innate activity. Set and setting are critical factors for the experience.\",\n+    \"subjective_effects\": [\n+      \"Visual Geometry (Organic, Intricate, Natural-Feeling)\",\n+      \"Colour Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Sedation With Mild Euphoria\",\n+      \"Pleasurable Body High (Warm, Tingling Sensations)\",\n+      \"Excessive Yawning\",\n+      \"Enhanced Music Appreciation\",\n+      \"Auditory Distortions (Downward Pitch Shift)\",\n+      \"Emotion Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Internal Hallucinations (Dark Environments)\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-MiPT Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/4_acetoxy_mipt/4_acetoxy_mipt.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-AcO-MIPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=pk&id=5546\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-AcO-MiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-MiPT\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy 4-AcO-MiPT Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-4-aco-mipt-thread.101872/\"\n+      },\n+      {\n+        \"name\": \"Takahashi et al. - Psychoactive Designer Drugs Data Library\",\n+        \"reference\": \"https://doi.org/10.1016/j.talanta.2008.07.062\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 639\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-235801-dbfacf25",
    "createdAt": "2025-10-16T23:58:01.469Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:57:59 PM"
    },
    "articles": [
      {
        "id": 638,
        "title": "4-AcO-DiPT",
        "slug": "4-aco-dipt"
      }
    ],
    "markdown": "# 4-AcO-DiPT · #638\n\n+{\n+  \"title\": \"4-AcO-DiPT\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"4-AcO-DiPT\",\n+    \"chemical_name\": \"3-[2-(Diisopropylamino)ethyl]-1H-indol-4-yl acetate\",\n+    \"alternative_name\": \"4-Acetoxy-DiPT; Ipracetin; Iprocetyl; Aces; 4-Ace\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"3-5 mg\",\n+            \"light\": \"5-15 mg\",\n+            \"common\": \"15-30 mg\",\n+            \"strong\": \"30-45 mg\",\n+            \"heavy\": \"45+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-4 hours\",\n+            \"onset\": \"15-40 minutes\",\n+            \"peak\": \"1.5-2 hours\",\n+            \"offset\": \"1-1.5 hours\",\n+            \"after_effects\": \"2-6 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"4-AcO-DiPT is not known to be habit-forming and the desire to use it can decrease with repeated administration. However, it may possess a higher liability for frequent or excessive consumption relative to most psychedelics due to its distinctly hedonic and short-duration effects. Compulsive redosing is reported to be atypically prominent for this substance.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"MAOIs (risk of serotonin syndrome)\",\n+        \"Stimulants (increased risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (may significantly intensify and prolong effects unpredictably)\",\n+        \"Alcohol (physically taxing, may dull effects)\",\n+        \"Benzodiazepines (may reduce trip intensity)\"\n+      ]\n+    },\n+    \"notes\": \"4-AcO-DiPT is thought to act as a prodrug to 4-HO-DiPT (Iprocin). It is available in both freebase and HCl salt forms, with the freebase being approximately 10% more potent by weight. This substance is characterized by atypically strong physical euphoria and sensuality with minimal visual effects, distinguishing it from most other 4-substituted tryptamines. Accurate weighing with a milligram scale is essential. Individuals with personal or family histories of seizure disorders or psychotic conditions should avoid use. The compound can produce notable increases in body temperature, particularly at peak effects. Set and setting significantly influence the experience.\",\n+    \"subjective_effects\": [\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Increased Libido\",\n+      \"Sedation Followed By Stimulation\",\n+      \"Disinhibition\",\n+      \"Enhanced Sociability\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations\",\n+      \"Changes In Felt Bodily Form\",\n+      \"Music Appreciation Enhancement\",\n+      \"Empathy And Affection Enhancement\",\n+      \"Minimal Visual Effects\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (e.g., psilocybin, LSD, mescaline, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"2-4 hours (rapidly metabolized to 4-HO-DiPT)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Primer by Toad\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt_primer.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid 4-Acetoxy-DiPT Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/4_acetoxy_dipt/4_acetoxy_dipt.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: 4-AcO-DiPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/4-AcO-DiPT\"\n+      },\n+      {\n+        \"name\": \"Bluelight 4-AcO-DiPT Discussion Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/4-aco-dipt-new-experience-10-mg-dose-to-test-the-waters.493414/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: 4-AcO-DiPT\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5369\"\n+      },\n+      {\n+        \"name\": \"Human Hepatocyte 4-AcO-DiPT Metabolite Profiling Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC9413566/\"\n+      },\n+      {\n+        \"name\": \"Investigation of Structure-Activity Relationships of Psilocybin Analogues\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC8033608/\"\n+      },\n+      {\n+        \"name\": \"Pharmacologic Activity of Substituted Tryptamines Study\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10029822/\"\n+      },\n+      {\n+        \"name\": \"TiHKAL Entry #17: 4-HO-DiPT\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal17.shtml\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\",\n+      \"synthetic\"\n+    ]\n+  },\n+  \"id\": 638\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-235243-ca7cd977",
    "createdAt": "2025-10-16T23:52:43.680Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:52:42 PM"
    },
    "articles": [
      {
        "id": 637,
        "title": "EPT",
        "slug": "ept"
      }
    ],
    "markdown": "# EPT · #637\n\n+{\n+  \"title\": \"EPT\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"EPT\",\n+    \"chemical_name\": \"N-Ethyl-N-propyltryptamine\",\n+    \"alternative_name\": \"Ethylpropyltryptamine; N-Ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-1-amine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-80 mg\",\n+            \"strong\": \"80-110 mg\",\n+            \"heavy\": \"110+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"75-100 mg\",\n+            \"common\": \"100-150 mg\",\n+            \"strong\": \"150-200 mg\",\n+            \"heavy\": \"200+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-60 mg\",\n+            \"strong\": \"60-100 mg\",\n+            \"heavy\": \"100+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"5-20 minutes\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"2-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"1-3 hours\",\n+            \"onset\": \"1-5 minutes\",\n+            \"peak\": \"10-30 minutes\",\n+            \"offset\": \"30-90 minutes\",\n+            \"after_effects\": \"1-2 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"EPT does not appear to produce dependence and has low abuse potential, similar to other unsubstituted tryptamines like DMT, DET, and MET. Rapid tolerance development discourages frequent use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (seizure risk)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"MAOIs (unknown interactions with increased potency)\",\n+        \"Stimulants (increased anxiety and physical strain)\"\n+      ],\n+      \"caution\": [\n+        \"Other psychedelics (overwhelming intensity)\",\n+        \"Cannabis (may intensify anxiety or confusion)\"\n+      ]\n+    },\n+    \"notes\": \"EPT is a novel research chemical with very limited documentation and extremely sparse user reports. The toxicity profile is unknown and no scientific studies exist on its safety in humans. Effects are described as milder and less immersive than structurally similar tryptamines like DMT and DPT. EPT is typically sold as the fumarate salt rather than the hydrochloride form. Start with very low doses due to individual sensitivity variations and the lack of established safety data. Use precise milligram scales and practice comprehensive harm reduction including set and setting protocols.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Color Enhancement\",\n+      \"Drifting And Morphing\",\n+      \"Dissociative Feeling\",\n+      \"Body Heaviness\",\n+      \"Time Distortion\",\n+      \"Memory Suppression\",\n+      \"Increased Libido\",\n+      \"Nausea\",\n+      \"Motor Control Loss\",\n+      \"Pupil Dilation\",\n+      \"Thought Acceleration\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, DMT, other tryptamines)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Small & Handy EPT Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-small-handy-ept-thread.856610/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: EPT Experiences\",\n+        \"reference\": \"https://drugs-forum.com/threads/ept-experiences.298861/\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: EPT\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_EPT.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: EPT\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5075\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: EPT\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/EPT\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 637\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-234801-e17fa4f6",
    "createdAt": "2025-10-16T23:48:01.414Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:47:59 PM"
    },
    "articles": [
      {
        "id": 636,
        "title": "DET",
        "slug": "det"
      }
    ],
    "markdown": "# DET · #636\n\n+{\n+  \"title\": \"DET\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"DET\",\n+    \"chemical_name\": \"N,N-diethyl-2-(1H-indol-3-yl)ethanamine\",\n+    \"alternative_name\": \"Diethyltryptamine; N,N-diethyltryptamine; T-9\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-70 mg\",\n+            \"strong\": \"70-100 mg\",\n+            \"heavy\": \"100+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"2-8 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"DET is not believed to be habit-forming and the desire to use it can actually decrease with repeated use. No formal studies have been conducted on its addiction potential, but anecdotal evidence suggests no negative dependency patterns.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (seizure risk and amplified intensity)\",\n+        \"MAOIs (serotonin syndrome risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (may cause anxiety, paranoia, and thought loops)\"\n+      ]\n+    },\n+    \"notes\": \"DET is a Schedule I controlled substance internationally under the UN Convention on Psychotropic Substances and is illegal in most countries. Unlike DMT, DET is orally active due to increased resistance to monoamine oxidase breakdown from its ethyl groups. The substance has extremely limited history of human use and no formal toxicity studies exist. Users should employ precise dosing with a milligram scale and ensure proper set and setting. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Pattern Recognition Enhancement\",\n+      \"Color Enhancement\",\n+      \"Drifting and Morphing\",\n+      \"Internal Hallucinations\",\n+      \"Cognitive Euphoria\",\n+      \"Emotion Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Time Distortion\",\n+      \"Pupil Dilation\",\n+      \"Nausea\",\n+      \"Increased Heart Rate\",\n+      \"Conceptual Thinking\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid DET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/det/det.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: DET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/DET\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #3: DET (Isomer Design)\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5003\"\n+      },\n+      {\n+        \"name\": \"TiHKAL #3: DET (Erowid)\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal03.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: 5-substituted tryptamines discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/5-substituted-tryptamines.340503/\"\n+      },\n+      {\n+        \"name\": \"Drug-drug interactions involving classic psychedelics\",\n+        \"reference\": \"https://pmc.ncbi.nlm.nih.gov/articles/PMC10851641/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 636\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-233259-3b3ee166",
    "createdAt": "2025-10-16T23:32:59.430Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 5:32:57 PM"
    },
    "articles": [
      {
        "id": 635,
        "title": "PRO-LAD",
        "slug": "pro-lad"
      }
    ],
    "markdown": "# PRO-LAD · #635\n\n+{\n+  \"title\": \"PRO-LAD\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"PRO-LAD\",\n+    \"chemical_name\": \"(8beta)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide\",\n+    \"alternative_name\": \"N-Propylnorlysergic acid N,N-diethylamide; 6-Propyl-6-nor-lysergic acid diethylamide; N-PropylnorLSD\",\n+    \"chemical_class\": \"Lysergamide\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20 ug\",\n+            \"light\": \"50-100 ug\",\n+            \"common\": \"100-200 ug\",\n+            \"strong\": \"200-350 ug\",\n+            \"heavy\": \"350+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-45 minutes\",\n+            \"peak\": \"2-4 hours\",\n+            \"offset\": \"2-3 hours\",\n+            \"after_effects\": \"1-4 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"PRO-LAD is not considered habit-forming and possesses self-regulating properties typical of psychedelics. The desire to use it may actually decrease with repeated administration. No formal dependence studies have been conducted.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of seizures and psychosis)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants including amphetamines, cocaine, methylphenidate (increased risk of anxiety, paranoia, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, and psychosis)\",\n+        \"MDMA (unpredictable synergy with potential neurotoxicity)\",\n+        \"Benzodiazepines (can reduce or eliminate psychedelic effects)\",\n+        \"Dissociatives (greatly enhanced effects and confusion)\",\n+        \"Other psychedelics (unpredictable synergistic intensification)\"\n+      ]\n+    },\n+    \"notes\": \"PRO-LAD is a research chemical with very limited history of human use and minimal scientific documentation regarding its pharmacology, metabolism, and long-term toxicity. Unlike LSD, PRO-LAD has a propyl chain at R6 which may result in slower absorption and different onset characteristics. Users should employ rigorous harm reduction practices including reagent testing, accurate weighing with a microgram scale, and having a trusted sober trip sitter present. Individuals with personal or family history of psychotic disorders should avoid use. PRO-LAD was first synthesized by Hoffman and Nichols in 1984 and later described by Alexander Shulgin in TiHKAL.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Color Enhancement\",\n+      \"Introspection\",\n+      \"Time Distortion\",\n+      \"Ego Death\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Enhanced Sense Of Humor\",\n+      \"Thought Connectivity\",\n+      \"Physical Euphoria\",\n+      \"Emotional Amplification\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and other lysergamides\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #51: PRO-LAD\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/tihkal51.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: PRO-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/PRO-LAD\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Hoffman AJ, Nichols DE (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry 28(9):1252-1255\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+      },\n+      {\n+        \"name\": \"Shulgin A, Shulgin A (1997). TiHKAL: Tryptamines I Have Known And Loved\",\n+        \"reference\": \"https://www.erowid.org/library/books_online/tihkal/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 635\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-225756-89bd9e8d",
    "createdAt": "2025-10-16T22:57:56.453Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:57:54 PM"
    },
    "articles": [
      {
        "id": 634,
        "title": "LSM-775",
        "slug": "lsm-775"
      }
    ],
    "markdown": "# LSM-775 · #634\n\n+{\n+  \"title\": \"LSM-775\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"LSM-775\",\n+    \"chemical_name\": \"[(8beta)-6-Methyl-9,10-didehydroergolin-8-yl](morpholin-4-yl)methanone\",\n+    \"alternative_name\": \"Lysergic acid morpholide; N-Morpholinyllysergamide; LA-Morph; LSM\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT1A receptor full agonist; 5-HT2A receptor partial agonist; 5-HT2B receptor partial agonist; 5-HT2C receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"250 ug\",\n+            \"light\": \"500-750 ug\",\n+            \"common\": \"750-1250 ug\",\n+            \"strong\": \"1250-1500 ug\",\n+            \"heavy\": \"1500+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"6-10 hours\",\n+            \"onset\": \"10-30 minutes\",\n+            \"peak\": \"60-150 minutes\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"Variable (residual sedation possible)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"LSM-775 is not considered habit-forming and possesses an intrinsic self-regulating quality similar to other psychedelics. Limited evidence suggests no significant dependence potential, though the substance has very little history of human use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increases anxiety, paranoia, and thought loops)\",\n+        \"Cannabis (unpredictable synergy; greatly increases risk of anxiety and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"MDMA (unpredictable synergy; potentially neurotoxic)\",\n+        \"Alcohol (increases dehydration and physical discomfort)\",\n+        \"Other psychedelics (unpredictable intensification)\"\n+      ]\n+    },\n+    \"notes\": \"LSM-775 is a novel lysergamide with approximately one-tenth the potency of LSD and a shorter duration. It is characterized by prominent dream-like sedation and significant nausea that may substantially reduce the experience's pleasantness. Use a precise milligram scale as doses are relatively high. Mental health screening is advised before use, particularly for individuals with personal or family history of psychotic disorders. Set and setting remain important factors. Legal status varies by jurisdiction; controlled in Germany and Switzerland as of 2019.\",\n+    \"subjective_effects\": [\n+      \"Dream-Like Sedation\",\n+      \"Prominent Nausea\",\n+      \"Visual Patterning And Geometry\",\n+      \"Time Distortion (Particularly Pronounced)\",\n+      \"Color Enhancement\",\n+      \"Spontaneous Physical Sensations (Tingling)\",\n+      \"Music Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Perception Of Bodily Heaviness\",\n+      \"Drifting (Melting, Breathing, Morphing)\",\n+      \"Internal Hallucinations\",\n+      \"Analysis Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin, mescaline, etc.)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: LSM-775\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSM-775\"\n+      },\n+      {\n+        \"name\": \"Erowid Experience Vaults: LSM-775\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_LSM775.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: LSM-775\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy LSM-775 Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-lsm-775-lysergic-acid-morpholide-thread.775765/\"\n+      },\n+      {\n+        \"name\": \"Gogerty & Dille (1957): Pharmacology of d-LSM\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/13476356/\"\n+      },\n+      {\n+        \"name\": \"Shulgin: TiHKAL - LSD-25 Entry\",\n+        \"reference\": \"https://isomerdesign.com/PiHKAL/explore.php?domain=tk&id=5338\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2018): Return of the Lysergamides Part IV\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/28585392/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"novel-psychoactive-substance\"\n+    ]\n+  },\n+  \"id\": 634\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-224845-2e3cf1ee",
    "createdAt": "2025-10-16T22:48:45.174Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:48:42 PM"
    },
    "articles": [
      {
        "id": 633,
        "title": "MET",
        "slug": "met"
      }
    ],
    "markdown": "# MET · #633\n\n+{\n+  \"title\": \"MET\",\n+  \"index-category\": \"psychedelic; tryptamine\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MET\",\n+    \"chemical_name\": \"N-Ethyl-N-methyltryptamine\",\n+    \"alternative_name\": \"Methylethyltryptamine\",\n+    \"chemical_class\": \"Tryptamines\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; serotonin releasing agent (weak)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked/vaporized\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10 mg\",\n+            \"light\": \"20-40 mg\",\n+            \"common\": \"40-60 mg\",\n+            \"strong\": \"60-90 mg\",\n+            \"heavy\": \"90+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"60-70 mg\",\n+            \"light\": \"70-80 mg\",\n+            \"common\": \"80-110 mg\",\n+            \"strong\": \"110-150 mg\",\n+            \"heavy\": \"150+ mg\"\n+          }\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"10-15 mg\",\n+            \"light\": \"15-30 mg\",\n+            \"common\": \"30-50 mg\",\n+            \"strong\": \"50-70 mg\",\n+            \"heavy\": \"70+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"smoked/vaporized\",\n+          \"stages\": {\n+            \"total_duration\": \"30-75 minutes\",\n+            \"onset\": \"30-60 seconds\",\n+            \"peak\": \"10-20 minutes\",\n+            \"offset\": \"20-40 minutes\",\n+            \"after_effects\": \"20-60 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"2-4 hours\",\n+            \"onset\": \"20-45 minutes\",\n+            \"peak\": \"1-2 hours\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"1-3 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"insufflated\",\n+          \"stages\": {\n+            \"total_duration\": \"1.5-3 hours\",\n+            \"onset\": \"5-15 minutes\",\n+            \"peak\": \"30-90 minutes\",\n+            \"offset\": \"45-90 minutes\",\n+            \"after_effects\": \"30-120 minutes\"\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"MET is not considered habit-forming and appears to be self-regulating. Reports suggest the desire to use it may actually decrease with regular consumption, similar to other psychedelic tryptamines.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of serotonin syndrome and hypertensive crisis)\",\n+        \"Lithium (increased seizure risk)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold)\",\n+        \"Stimulants (increased risk of anxiety and cardiovascular strain)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may dampen or prolong effects)\",\n+        \"Cannabis (may intensify experience unpredictably)\"\n+      ]\n+    },\n+    \"notes\": \"MET is a research chemical with very limited human use history and unstudied toxicity profile. The freebase form can be harsh when insufflated or smoked. Use an accurate milligram scale for all routes of administration. Set and setting are crucial for psychedelic experiences. Unlike DMT, MET has oral activity without requiring an MAOI. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Visual Geometry And Patterning\",\n+      \"Internal Hallucinations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Stimulation\",\n+      \"Color Enhancement And Shifting\",\n+      \"Cognitive Euphoria\",\n+      \"Empathy And Sociability Enhancement\",\n+      \"Thought Connectivity\",\n+      \"Time Distortion\",\n+      \"Confusion\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Minimal tolerance buildup with repeated use\",\n+      \"half_tolerance\": \"Unknown\",\n+      \"zero_tolerance\": \"Approximately 1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"Other psychedelic tryptamines (minimal to none)\",\n+        \"Classic psychedelics (minimal to none)\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy MET Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-met-thread.255405/\"\n+      },\n+      {\n+        \"name\": \"Erowid MET Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/met/met.shtml\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: MET\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MET\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Methylethyltryptamine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Methylethyltryptamine\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"tryptamine\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 633\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-224503-b5466f8d",
    "createdAt": "2025-10-16T22:45:03.789Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:45:01 PM"
    },
    "articles": [
      {
        "id": 632,
        "title": "MiPLA",
        "slug": "mipla"
      }
    ],
    "markdown": "# MiPLA · #632\n\n+{\n+  \"title\": \"MiPLA\",\n+  \"index-category\": \"psychedelic; lysergamide; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"MiPLA\",\n+    \"chemical_name\": \"(6aR,9R)-N-methyl-N-isopropyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"alternative_name\": \"Lamide; Methylisopropyllysergamide; N-Methyl-N-isopropyllysergamide\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"50 ug\",\n+            \"light\": \"100-150 ug\",\n+            \"common\": \"150-200 ug\",\n+            \"strong\": \"200-250 ug\",\n+            \"heavy\": \"300+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"4-6 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"1-2 hours (preceded by 45-90 minute come-up)\",\n+            \"offset\": \"1-2 hours\",\n+            \"after_effects\": \"Minimal residual stimulation\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"MiPLA is not considered physically addictive and has low potential for psychological dependence, similar to other serotonergic psychedelics. Rapid tolerance development discourages frequent use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (amphetamine, cocaine, methylphenidate - increases risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"SSRIs (may alter or blunt effects)\"\n+      ]\n+    },\n+    \"notes\": \"MiPLA is a research chemical with very limited history of human use and minimal scientific study of its pharmacology, metabolism, and toxicity. It is approximately two to three times less potent than LSD and has a notably shorter duration of around 4-6 hours. The substance is generally described as producing less anxiety and a lighter headspace compared to LSD. Individuals with personal or family history of mental illness should avoid use. Use precise weighing equipment and employ harm reduction practices including careful set and setting preparation.\",\n+    \"subjective_effects\": [\n+      \"Stimulation\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Visual Acuity Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Geometric Patterns\",\n+      \"Cognitive Euphoria\",\n+      \"Analysis Enhancement\",\n+      \"Music Appreciation Enhancement\",\n+      \"Time Distortion\",\n+      \"Ego Death (at higher doses)\",\n+      \"Nausea\",\n+      \"Increased Body Temperature\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (due to 5-HT2A receptor activity)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (estimated based on duration profile)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: MiPLA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/MiPLA\"\n+      },\n+      {\n+        \"name\": \"Erowid MiPLA Experience Vault\",\n+        \"reference\": \"https://erowid.org/experiences/subs/exp_MIPLA.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy MIPLA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-mipla-methylisopropyllysergamide-thread.784440/\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: MiPLA (PiHKAL)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/explore/5327\"\n+      },\n+      {\n+        \"name\": \"Halberstadt et al. (2018) - Pharmacological characterization of ECPLA\",\n+        \"reference\": \"https://link.springer.com/article/10.1007/s00213-018-5055-9\"\n+      },\n+      {\n+        \"name\": \"Nichols, D.E. (2001) - LSD and its lysergamide cousins\",\n+        \"reference\": \"The Heffter Review of Psychedelic Research, Vol. 2, pp. 80-87\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 632\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223851-15e5eaa2",
    "createdAt": "2025-10-16T22:38:51.510Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:38:49 PM"
    },
    "articles": [
      {
        "id": 631,
        "title": "LSA",
        "slug": "lsa"
      }
    ],
    "markdown": "# LSA · #631\n\n+{\n+  \"title\": \"LSA\",\n+  \"index-category\": \"psychedelic; natural\",\n+  \"drug_info\": {\n+    \"drug_name\": \"LSA\",\n+    \"chemical_name\": \"(8β)-9,10-Didehydro-6-methyl-ergoline-8-carboxamide\",\n+    \"alternative_name\": \"Ergine; d-Lysergic acid amide; d-Lysergamide; LA-111\",\n+    \"chemical_class\": \"Lysergamide; Ergoline alkaloid\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"20-50 seeds\",\n+            \"light\": \"50-100 seeds\",\n+            \"common\": \"100-250 seeds\",\n+            \"strong\": \"250-400 seeds\",\n+            \"heavy\": \"400+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"units\": \"seeds\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"1-3 seeds\",\n+            \"light\": \"3-5 seeds\",\n+            \"common\": \"5-7 seeds\",\n+            \"strong\": \"7-12 seeds\",\n+            \"heavy\": \"12+ seeds\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"0.5 mg\",\n+            \"light\": \"0.5-1 mg\",\n+            \"common\": \"1-2 mg\",\n+            \"strong\": \"2-3 mg\",\n+            \"heavy\": \"3+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral (morning glory seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        },\n+        {\n+          \"route\": \"oral (hawaiian baby woodrose seeds)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        },\n+        {\n+          \"route\": \"oral (pure lsa)\",\n+          \"stages\": {\n+            \"total_duration\": \"4-10 hours\",\n+            \"onset\": \"20-60 minutes (up to 3 hours reported)\",\n+            \"peak\": \"90-180 minutes\",\n+            \"offset\": \"2-7 hours\",\n+            \"after_effects\": \"1-12 hours (afterglow)\"\n+          }\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"LSA is not considered to be addictive with low abuse potential. There is virtually no withdrawal syndrome when use is stopped, and animal studies have not demonstrated self-administration behavior predictive of abuse liability.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (increased risk of anxiety, paranoia, thought loops, and mania)\",\n+        \"Cannabis (unexpectedly strong and unpredictable synergy; significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"SSRIs (may suppress visual and cognitive effects)\",\n+        \"MAOIs (may potentiate effects; use caution with potential for dangerous interactions with other substances)\",\n+        \"Dissociatives (greatly enhance cognitive, visual and hallucinatory effects with increased risk of confusion and psychosis)\",\n+        \"Alcohol (may reduce anxiety but can increase dehydration, nausea and physical fatigue)\",\n+        \"Benzodiazepines (can reduce trip intensity; useful for stopping bad trips but may cause amnesia)\",\n+        \"Other psychedelics (unpredictable synergy and intensification of effects)\"\n+      ]\n+    },\n+    \"notes\": \"LSA-containing seeds vary widely in alkaloid content between species, batches, and individual seeds. Commercial seeds are often treated with fungicides or pesticides that can be extremely toxic; only use organic, untreated seeds from trusted vendors. Heavy metal testing is recommended before consumption. Extraction methods can significantly reduce nausea and body load. Strong vasoconstriction is common and can cause painful leg cramping; avoid repeated use over short periods. Set and setting strongly influence the experience. Individuals with personal or family histories of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Sedation (setting-dependent)\",\n+      \"Physical Euphoria\",\n+      \"Visual Enhancements and Distortions\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Perception of Bodily Heaviness\",\n+      \"Motor Control Loss\",\n+      \"Nausea and Vasoconstriction\",\n+      \"Dream-Like State\",\n+      \"Introspection and Analysis Enhancement\",\n+      \"Emotion Enhancement\",\n+      \"Time Distortion\",\n+      \"Internal and External Hallucinations\",\n+      \"Thought Connectivity\",\n+      \"Music Appreciation Enhancement\",\n+      \"Spirituality Enhancement\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Almost immediately after ingestion\",\n+      \"half_tolerance\": \"3-4 days\",\n+      \"zero_tolerance\": \"7 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (LSD, psilocybin mushrooms, mescaline, DMT, 2C-x compounds)\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (psilocin is referenced in the original document, but LSA half-life data is limited; serum concentrations detectable for 1-24 hours post-ingestion)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: LSA\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: LSA\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Vault\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Dosage\",\n+        \"reference\": \"https://erowid.org/chemicals/lsa/lsa_dose.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid LSA Effects\",\n+        \"reference\": \"https://www.erowid.org/chemicals/lsa/lsa_effects.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy LSA Thread\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/lsas-subthread-extraction-of-lsas.123944/\"\n+      },\n+      {\n+        \"name\": \"Drugs-Forum: LSA Wiki\",\n+        \"reference\": \"https://drugs-forum.com/wiki/LSA\"\n+      },\n+      {\n+        \"name\": \"Wikipedia: Ergine\",\n+        \"reference\": \"https://en.wikipedia.org/wiki/Ergine\"\n+      },\n+      {\n+        \"name\": \"Lysergic Acid Amide (LSA), an LSD Analog: Systematic Review (MDPI, 2025)\",\n+        \"reference\": \"https://www.mdpi.com/2226-4787/13/4/98\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"natural\",\n+      \"ergoline\"\n+    ]\n+  },\n+  \"id\": 631\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223526-fd17483e",
    "createdAt": "2025-10-16T22:35:26.906Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:35:25 PM"
    },
    "articles": [
      {
        "id": 630,
        "title": "ETH-LAD",
        "slug": "eth-lad"
      }
    ],
    "markdown": "# ETH-LAD · #630\n\n+{\n+  \"title\": \"ETH-LAD\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"ETH-LAD\",\n+    \"chemical_name\": \"(6aR,9R)-N,N,7-Triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide\",\n+    \"alternative_name\": \"N-Ethyl-nor-LSD; 6-Ethyl-6-nor-lysergic acid diethylamide; N-Ethyl-nor-lysergic acid N,N-diethylamide\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor agonist; 5-HT2C receptor agonist; 5-HT1A receptor agonist (high affinity); dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"30-60 ug\",\n+            \"common\": \"60-150 ug\",\n+            \"strong\": \"150-225 ug\",\n+            \"heavy\": \"225+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"4-6 hours (including 45-90 minute come up)\",\n+            \"offset\": \"2-4 hours\",\n+            \"after_effects\": \"8-48 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"ETH-LAD is not considered habit-forming and demonstrates a self-regulating quality typical of psychedelics. Rapid tolerance develops immediately after use, discouraging frequent consumption. Cases of abuse have been rarely reported, though the substance generally decreases in desirability with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increased risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Cannabis (unpredictable and strongly increased effects, risk of anxiety, paranoia, panic attacks, and psychosis)\",\n+        \"Stimulants including amphetamine, cocaine, methylphenidate (increased risk of anxiety, paranoia, panic attacks, thought loops, mania, and psychosis)\"\n+      ],\n+      \"caution\": []\n+    },\n+    \"notes\": \"ETH-LAD requires exceptional caution due to its high potency, unpredictable dose-response curve, and tendency to produce severe physical side effects including pronounced nausea, temperature dysregulation, muscle cramps, and bodily discomfort at higher doses. The substance is notably more difficult to handle than LSD and should only be used by experienced psychedelic users. Accurate measurement with a precise scale is critical. Users should monitor body temperature throughout the experience and maintain access to climate control. Set and setting are paramount, and having a trusted sober sitter is strongly recommended, especially at doses above the common range. Individuals with personal or family history of psychotic disorders should avoid use.\",\n+    \"subjective_effects\": [\n+      \"Intricate Visual Geometry\",\n+      \"Enhanced Pattern Recognition\",\n+      \"Auditory Distortions and Hallucinations\",\n+      \"Analysis Enhancement\",\n+      \"Introspective Thought Patterns\",\n+      \"Time Distortion\",\n+      \"Synaesthesia\",\n+      \"Enhanced Color Perception\",\n+      \"Nausea and Bodily Discomfort\",\n+      \"Temperature Dysregulation\",\n+      \"Emotional Neutrality or Detachment\",\n+      \"Thought Acceleration\",\n+      \"Memory Suppression\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Develops almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin, mescaline, DMT, and related lysergamides\"\n+      ]\n+    },\n+    \"half_life\": \"\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Bluelight: The Big & Dandy ETH-LAD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-big-dandy-eth-lad-thread.761505/\"\n+      },\n+      {\n+        \"name\": \"Erowid ETH-LAD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_ETHLAD.shtml\"\n+      },\n+      {\n+        \"name\": \"Erowid TiHKAL Entry #12: ETH-LAD\",\n+        \"reference\": \"https://erowid.org/library/books_online/tihkal/tihkal12.shtml\"\n+      },\n+      {\n+        \"name\": \"Hoffman AJ, Nichols DE (1985) - Synthesis and LSD-like discriminative stimulus properties\",\n+        \"reference\": \"https://doi.org/10.1021/jm00147a022\"\n+      },\n+      {\n+        \"name\": \"Isomer Design: TiHKAL ETH-LAD Entry\",\n+        \"reference\": \"http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=12\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: ETH-LAD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ETH-LAD\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\"\n+    ]\n+  },\n+  \"id\": 630\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-223152-65eead67",
    "createdAt": "2025-10-16T22:31:52.581Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:31:51 PM"
    },
    "articles": [
      {
        "id": 629,
        "title": "ALD-52",
        "slug": "ald-52"
      }
    ],
    "markdown": "# ALD-52 · #629\n\n+{\n+  \"title\": \"ALD-52\",\n+  \"index-category\": \"psychedelic; lysergamide\",\n+  \"drug_info\": {\n+    \"drug_name\": \"ALD-52\",\n+    \"chemical_name\": \"(6aR,9R)-4-Acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]-quinoline-9-carboxamide\",\n+    \"alternative_name\": \"1-Acetyl-LSD; 1A-LSD; 1A-LAD; Orange Sunshine\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist; 5-HT2C receptor partial agonist; 5-HT1A receptor partial agonist; D2 receptor agonist (through LSD metabolite)\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"30 ug\",\n+            \"light\": \"30-100 ug\",\n+            \"common\": \"100-175 ug\",\n+            \"strong\": \"175-325 ug\",\n+            \"heavy\": \"325+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-14 hours\",\n+            \"onset\": \"20-40 minutes\",\n+            \"peak\": \"3-5 hours (following 1-2 hour come up)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"4-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"ALD-52 is not considered physically addictive and has extremely low potential for psychological dependence. The rapid development of tolerance discourages frequent use patterns, and the desire to use typically decreases with repeated exposure rather than increasing.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"MAOIs (unpredictable effects, possible hypertensive reaction)\"\n+      ],\n+      \"unsafe\": [\n+        \"Tramadol (lowers seizure threshold, psychedelics may trigger seizures)\",\n+        \"Stimulants including amphetamines and cocaine (increased risk of anxiety, thought loops, cardiovascular strain)\"\n+      ],\n+      \"caution\": [\n+        \"Cannabis (unpredictably strong synergy, increased risk of anxiety and paranoia)\",\n+        \"MDMA (may increase neurotoxicity, unpredictable synergy)\",\n+        \"Other psychedelics (intense cross-tolerance and potentially overwhelming effects)\",\n+        \"SSRIs (may blunt or alter effects)\"\n+      ]\n+    },\n+    \"notes\": \"ALD-52 functions as a prodrug for LSD, metabolizing into LSD in the body along with other metabolites. Legal status varies widely by jurisdiction; it is controlled in many countries including the UK, Germany, Switzerland, and Latvia, while remaining technically unscheduled in others such as the United States and Denmark. Individuals with personal or family history of psychotic disorders should avoid use. Famous for being mistakenly associated with 'Orange Sunshine' LSD from the 1960s, though this was later confirmed to be standard LSD at 300 micrograms per dose. Set and setting are critical for a positive experience, and users should approach this potent, long-lasting substance with proper preparation and harm reduction practices.\",\n+    \"subjective_effects\": [\n+      \"Visual Patterning And Geometry\",\n+      \"Enhanced Sensory Perception\",\n+      \"Time Distortion\",\n+      \"Cognitive Euphoria\",\n+      \"Enhanced Introspection\",\n+      \"Emotional Amplification\",\n+      \"Physical Euphoria\",\n+      \"Thought Acceleration\",\n+      \"Enhanced Music Appreciation\",\n+      \"Pupil Dilation\",\n+      \"Increased Energy And Stimulation\",\n+      \"Novel Thought Patterns\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Immediately after ingestion, cross-tolerant with all psychedelics\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics including LSD, psilocybin mushrooms, mescaline, and tryptamines\"\n+      ]\n+    },\n+    \"half_life\": \"1-3 hours (LSD active metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid ALD-52 Vault\",\n+        \"reference\": \"https://erowid.org/chemicals/lsd/lsd_ald52.shtml\"\n+      },\n+      {\n+        \"name\": \"Isomer Design TiHKAL Entry 26 (LSD)\",\n+        \"reference\": \"https://isomerdesign.com/pihkal/read/tk/26\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: ALD-52\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/ALD-52\"\n+      },\n+      {\n+        \"name\": \"The Big & Dandy ALD-52 Thread (Bluelight)\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/the-big-dandy-ald-52-thread.773316/\"\n+      },\n+      {\n+        \"name\": \"TripSit Drug Combination Chart\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Drug_combinations\"\n+      },\n+      {\n+        \"name\": \"Wagmann et al. (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances\",\n+        \"reference\": \"https://doi.org/10.1007/s00216-018-1558-9\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n+    ]\n+  },\n+  \"id\": 629\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-222911-e7a3cfaa",
    "createdAt": "2025-10-16T22:29:11.119Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:29:09 PM"
    },
    "articles": [
      {
        "id": 628,
        "title": "1V-LSD",
        "slug": "1v-lsd"
      }
    ],
    "markdown": "# 1V-LSD · #628\n\n+{\n+  \"title\": \"1V-LSD\",\n+  \"index-category\": \"psychedelic; research-chemical\",\n+  \"drug_info\": {\n+    \"drug_name\": \"1V-LSD\",\n+    \"chemical_name\": \"1-Valeroyl-d-lysergic acid diethylamide\",\n+    \"alternative_name\": \"Valerie; 1-Valeryl-LSD; 1-Pentanoyl-LSD\",\n+    \"chemical_class\": \"Lysergamides\",\n+    \"psychoactive_class\": \"Psychedelic\",\n+    \"mechanism_of_action\": \"5-HT2A receptor partial agonist (weak); acts as prodrug for LSD via deacylation\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"ug\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"15 ug\",\n+            \"light\": \"25-75 ug\",\n+            \"common\": \"75-150 ug\",\n+            \"strong\": \"150-300 ug\",\n+            \"heavy\": \"300+ ug\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"8-12 hours\",\n+            \"onset\": \"20-60 minutes\",\n+            \"peak\": \"3-5 hours (come up 45-120 minutes)\",\n+            \"offset\": \"3-5 hours\",\n+            \"after_effects\": \"6-24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"1V-LSD is assumed to be non-addictive with low abuse potential, similar to LSD. No literature reports exist of successful attempts to train animals to self-administer LSD analogs. There is virtually no withdrawal syndrome when chronic use is stopped.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"Lithium (significantly increases risk of psychosis and seizures)\",\n+        \"Tramadol (lowers seizure threshold)\"\n+      ],\n+      \"unsafe\": [\n+        \"Cannabis (strong synergy, significantly increases risk of anxiety, paranoia, panic attacks, and psychosis)\"\n+      ],\n+      \"caution\": [\n+        \"Stimulants (may increase risk of anxiety, paranoia, panic attacks, thought loops, mania and psychosis)\",\n+        \"MDMA (unpredictable synergy, potential increased neurotoxicity)\",\n+        \"Dissociatives (enhanced hallucinatory effects, increased risk of confusion and delusions)\",\n+        \"Benzodiazepines (reduce intensity of effects)\",\n+        \"Alcohol (may reduce anxiety but causes dehydration and physical discomfort)\"\n+      ]\n+    },\n+    \"notes\": \"1V-LSD is a novel research chemical with minimal history of human use and unverified safety profile. It is presumed to act as a prodrug for LSD. Those with personal or family history of mental illness should avoid use, particularly outside supervised medical settings. Set and setting are critical factors in determining experience quality. Start with lower doses due to individual variations in body weight, tolerance, metabolism, and sensitivity. No toxic dose is known, but higher doses increase risk of adverse psychological reactions. Test substances with reagent kits, though Ehrlich's reagent reacts slowly with N-acylated lysergamides.\",\n+    \"subjective_effects\": [\n+      \"Geometric Visual Hallucinations\",\n+      \"Time Distortion\",\n+      \"Enhanced Introspection\",\n+      \"Ego Loss\",\n+      \"Stimulation\",\n+      \"Spontaneous Bodily Sensations\",\n+      \"Physical Euphoria\",\n+      \"Tactile Enhancement\",\n+      \"Color Enhancement\",\n+      \"Pattern Recognition Enhancement\",\n+      \"Visual Drifting\",\n+      \"Analysis Enhancement\",\n+      \"Conceptual Thinking\",\n+      \"Emotion Enhancement\",\n+      \"Cognitive Euphoria\",\n+      \"Creativity Enhancement\",\n+      \"Increased Music Appreciation\",\n+      \"Unity And Interconnectedness\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"Builds almost immediately after ingestion\",\n+      \"half_tolerance\": \"5-7 days\",\n+      \"zero_tolerance\": \"14 days\",\n+      \"cross_tolerances\": [\n+        \"All psychedelics (including LSD, psilocybin, mescaline, DMT)\"\n+      ]\n+    },\n+    \"half_life\": \"Similar to LSD (estimated 3-5 hours for active metabolite)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"PsychonautWiki: 1V-LSD\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/1V-LSD\"\n+      },\n+      {\n+        \"name\": \"Erowid 1V-LSD Experience Vault\",\n+        \"reference\": \"https://www.erowid.org/experiences/subs/exp_1VLSD.shtml\"\n+      },\n+      {\n+        \"name\": \"Bluelight: The Small & Handy 1V-LSD Thread\",\n+        \"reference\": \"https://bluelight.org/xf/threads/the-small-handy-1v-lsd-thread.904997/\"\n+      },\n+      {\n+        \"name\": \"Brandt et al. (2022): Return of the lysergamides Part VII - Analytical and behavioural characterization of 1V-LSD\",\n+        \"reference\": \"https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3205\"\n+      },\n+      {\n+        \"name\": \"Tripsitter: 1V-LSD - A New LSD Analog\",\n+        \"reference\": \"https://tripsitter.com/1v-lsd/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"psychedelic\",\n+      \"lysergamide\",\n+      \"research-chemical\",\n+      \"prodrug\"\n+    ]\n+  },\n+  \"id\": 628\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-222618-76ba04c5",
    "createdAt": "2025-10-16T22:26:18.516Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 4:26:16 PM"
    },
    "articles": [
      {
        "id": 626,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      },
      {
        "id": 627,
        "title": "Diphenhydramine",
        "slug": "diphenhydramine"
      }
    ],
    "markdown": "# Diphenhydramine · #626\n\n+{\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n+      ]\n+    },\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"subjective_effects\": [\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+      ]\n+    },\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n+      },\n+      {\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n+    ]\n+  },\n+  \"id\": 626\n+}\n\n# Diphenhydramine · #627\n\n+{\n+  \"title\": \"Diphenhydramine\",\n+  \"index-category\": \"deliriant; otc\",\n+  \"drug_info\": {\n+    \"drug_name\": \"Diphenhydramine\",\n+    \"chemical_name\": \"2-(Diphenylmethoxy)-N,N-dimethylethanamine\",\n+    \"alternative_name\": \"DPH; Benadryl; Nytol; Sominex; Unisom SleepMelts; ZzzQuil; Dimedrol\",\n+    \"chemical_class\": \"Ethanolamine\",\n+    \"psychoactive_class\": \"Deliriant\",\n+    \"mechanism_of_action\": \"H1 histamine receptor inverse agonist; muscarinic acetylcholine receptor antagonist; weak serotonin reuptake inhibition; sodium channel blockade; voltage-gated potassium channel blockade\",\n+    \"dosages\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"units\": \"mg\",\n+          \"dose_ranges\": {\n+            \"threshold\": \"25 mg\",\n+            \"light\": \"100-200 mg\",\n+            \"common\": \"200-400 mg\",\n+            \"strong\": \"400-700 mg\",\n+            \"heavy\": \"700+ mg\"\n+          }\n+        }\n+      ]\n+    },\n+    \"duration\": {\n+      \"routes_of_administration\": [\n+        {\n+          \"route\": \"oral\",\n+          \"stages\": {\n+            \"total_duration\": \"3-10 hours\",\n+            \"onset\": \"30-90 minutes\",\n+            \"peak\": \"1-4 hours\",\n+            \"offset\": \"2-6 hours\",\n+            \"after_effects\": \"Up to 24 hours\"\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n+        }\n+      ]\n+    },\n+    \"addiction_potential\": \"Diphenhydramine has low abuse potential due to its overwhelmingly dysphoric and unpleasant effects. While physical dependence is possible with chronic use, most users do not wish to repeat the experience. Tolerance develops rapidly with repeated use.\",\n+    \"interactions\": {\n+      \"dangerous\": [\n+        \"MAOIs (risk of severe anticholinergic effects)\",\n+        \"Anticholinergics (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"High doses of acetaminophen-containing formulations (liver damage, death)\"\n+      ],\n+      \"unsafe\": [\n+        \"Stimulants (severe tachycardia, heart attack risk, abnormal heart rhythm)\",\n+        \"Tramadol (increased seizure risk)\",\n+        \"Alcohol (dangerous sedation, respiratory depression)\"\n+      ],\n+      \"caution\": [\n+        \"Benzodiazepines (dangerous sedation, respiratory depression, visual suppression)\",\n+        \"SSRIs (visual suppression, potential serotonin syndrome)\",\n+        \"Opioids (increased sedation, respiratory depression)\"\n+      ]\n+    },\n+    \"notes\": \"Diphenhydramine is widely available over-the-counter and used medically for allergies and sleep aid. Recreational use produces intensely dysphoric and unpredictable deliriant effects including realistic hallucinations that users cannot distinguish from reality. The substance has significant cardiovascular risks including QT prolongation and potential for torsades de pointes. Always verify that products contain only diphenhydramine as active ingredient; many combination products contain acetaminophen or other drugs that can be fatal in high doses. A sober trip sitter is essential as users may respond to hallucinations and injure themselves. Chronic use may cause persistent cognitive impairment, memory damage, and has been linked to increased dementia risk.\",\n+    \"subjective_effects\": [\n+      \"Sedation and Body Heaviness\",\n+      \"External Hallucinations (People, Objects, Insects)\",\n+      \"Auditory Hallucinations (Voices, Screams)\",\n+      \"Tactile Hallucinations (Phantom Sensations)\",\n+      \"Shadow People\",\n+      \"Delirium and Confusion\",\n+      \"Memory Suppression and Amnesia\",\n+      \"Dysphoria and Anxiety\",\n+      \"Restless Leg Syndrome\",\n+      \"Dry Mouth and Dehydration\",\n+      \"Visual Acuity Suppression (Blurred Vision)\",\n+      \"Thought Disorganization\"\n+    ],\n+    \"tolerance\": {\n+      \"full_tolerance\": \"After 2-3 consecutive days of use\",\n+      \"half_tolerance\": \"3-5 days\",\n+      \"zero_tolerance\": \"1-2 weeks\",\n+      \"cross_tolerances\": [\n+        \"All deliriants (datura, scopolamine, dimenhydrinate)\"\n+      ]\n+    },\n+    \"half_life\": \"5 hours (pediatric); 9 hours (adult); 13.5 hours (elderly)\",\n+    \"citations\": [\n+      {\n+        \"name\": \"Erowid Diphenhydramine Vault\",\n+        \"reference\": \"https://www.erowid.org/pharms/diphenhydramine/\"\n+      },\n+      {\n+        \"name\": \"PsychonautWiki: Diphenhydramine\",\n+        \"reference\": \"https://psychonautwiki.org/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"TripSit Wiki: Diphenhydramine\",\n+        \"reference\": \"https://wiki.tripsit.me/wiki/Diphenhydramine\"\n+      },\n+      {\n+        \"name\": \"Bluelight: Diphenhydramine Discussion\",\n+        \"reference\": \"https://www.bluelight.org/community/threads/dph-trip.560305/\"\n+      },\n+      {\n+        \"name\": \"DrugBank: Diphenhydramine\",\n+        \"reference\": \"https://go.drugbank.com/drugs/DB01075\"\n+      },\n+      {\n+        \"name\": \"StatPearls: Diphenhydramine Toxicity\",\n+        \"reference\": \"https://www.ncbi.nlm.nih.gov/books/NBK557578/\"\n+      },\n+      {\n+        \"name\": \"Gray et al., 2015 - Cumulative Anticholinergic Use and Dementia\",\n+        \"reference\": \"https://pubmed.ncbi.nlm.nih.gov/25621434/\"\n+      }\n+    ],\n+    \"categories\": [\n+      \"deliriant\",\n+      \"depressant\",\n+      \"antihistamine\",\n+      \"otc\"\n+    ]\n+  },\n+  \"id\": 627\n+}",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251016-211713-87b4367c",
    "createdAt": "2025-10-16T21:17:13.242Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:17:09"
    },
    "articles": [
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      }
    ],
    "markdown": "# LSD · #191\n\n-    \"chemical_name\": \"LSD\",\n-    \"alternative_name\": \"Lysergic acid diethylamide\",\n+    \"chemical_name\": \"Lysergic acid diethylamide\",\n+    \"alternative_name\": \"Lucy; Acid\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"research-chemical\"\n+      \"common\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210951-3bc6b2e2",
    "createdAt": "2025-10-16T21:09:51.985Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:09:48"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 200,
        "title": "Psilocybin mushrooms",
        "slug": "psilocybin-mushrooms"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Psilocybin mushrooms · #200\n\n-  \"title\": \"Penis Envy\",\n+  \"title\": \"Psilocybin mushrooms\",\n-    \"drug_name\": \"Penis Envy\",\n-    \"chemical_name\": \"Penis Envy\",\n-    \"alternative_name\": \"Psilocybe cubensis, Penis Envy strain\",\n+    \"drug_name\": \"Psilocybin mushrooms\",\n+    \"chemical_name\": \"Psilocybin\",\n+    \"alternative_name\": \"Psilocybe cubensis; Magic mushrooms; Shrooms\",\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"research-chemical\"\n+      \"common\"\n\n# Amanita Muscaria · #201\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-120 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210536-524a89f5",
    "createdAt": "2025-10-16T21:05:36.034Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:05:33"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Amanita Muscaria · #201\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n+            \"total_duration\": \"6-8 hours\",\n+            \"onset\": \"30-120 minutes\",\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-      \"research-chemical\"\n+      \"research-chemical\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210425-092f4def",
    "createdAt": "2025-10-16T21:04:25.208Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:04:21"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Ibotenic acid · #215\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210204-b30f4dee",
    "createdAt": "2025-10-16T21:02:04.651Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 23:02:01"
    },
    "articles": [
      {
        "id": 242,
        "title": "Gaboxadol",
        "slug": "gaboxadol"
      },
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Gaboxadol · #242\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-210000-f6e22140",
    "createdAt": "2025-10-16T21:00:00.495Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:59:57"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Salvia · #409\n\n-          \"canonical_routes\": [\n-            \"smoked\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"smoked\"\n+          ]\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"other dissociatives\"\n+      \"other dissociatives\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205923-297a11ac",
    "createdAt": "2025-10-16T20:59:23.332Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:59:20"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 179,
        "title": "Zaleplon",
        "slug": "zaleplon"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zaleplon · #179\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205842-8929e224",
    "createdAt": "2025-10-16T20:58:42.976Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:58:39"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      },
      {
        "id": 183,
        "title": "Zolpidem",
        "slug": "zolpidem"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"\n\n# Zolpidem · #183\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-205804-77914f41",
    "createdAt": "2025-10-16T20:58:04.237Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:58:00"
    },
    "articles": [
      {
        "id": 176,
        "title": "Zopiclone",
        "slug": "zopiclone"
      }
    ],
    "markdown": "# Zopiclone · #176\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"gabaergic\"\n+      \"gabaergic\",\n+      \"A-typical Hallucinogen\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-204349-778df3a1",
    "createdAt": "2025-10-16T20:43:49.406Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 22:43:45"
    },
    "articles": [
      {
        "id": 59,
        "title": "Mescaline",
        "slug": "mescaline"
      },
      {
        "id": 60,
        "title": "5-MeO-DMT",
        "slug": "5-meo-dmt"
      },
      {
        "id": 73,
        "title": "4-HO-MET",
        "slug": "4-ho-met"
      },
      {
        "id": 79,
        "title": "EA-3167",
        "slug": "ea-3167"
      },
      {
        "id": 82,
        "title": "25I-NBOMe",
        "slug": "25i-nbome"
      },
      {
        "id": 102,
        "title": "4-AcO-DMT",
        "slug": "4-aco-dmt"
      },
      {
        "id": 106,
        "title": "Canket",
        "slug": "canket"
      },
      {
        "id": 107,
        "title": "FXE",
        "slug": "fxe"
      },
      {
        "id": 270,
        "title": "MAL",
        "slug": "mal"
      },
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      },
      {
        "id": 139,
        "title": "DOM",
        "slug": "dom"
      },
      {
        "id": 280,
        "title": "DOB",
        "slug": "dob"
      },
      {
        "id": 158,
        "title": "PMA",
        "slug": "pma"
      },
      {
        "id": 181,
        "title": "DiPT",
        "slug": "dipt"
      },
      {
        "id": 189,
        "title": "DXM Polistirex",
        "slug": "dxm-polistirex"
      },
      {
        "id": 191,
        "title": "LSD",
        "slug": "lsd"
      },
      {
        "id": 196,
        "title": "Ibogaine",
        "slug": "ibogaine"
      },
      {
        "id": 199,
        "title": "Yopo",
        "slug": "yopo"
      },
      {
        "id": 200,
        "title": "Penis Envy",
        "slug": "penis-envy"
      },
      {
        "id": 205,
        "title": "Bromo-DragonFLY",
        "slug": "bromo-dragonfly"
      },
      {
        "id": 206,
        "title": "Kratom",
        "slug": "kratom"
      },
      {
        "id": 201,
        "title": "Amanita Muscaria",
        "slug": "amanita-muscaria"
      },
      {
        "id": 215,
        "title": "Ibotenic acid",
        "slug": "ibotenic-acid"
      },
      {
        "id": 222,
        "title": "DOET",
        "slug": "doet"
      },
      {
        "id": 80,
        "title": "3-Quinuclidinyl benzilate",
        "slug": "3-quinuclidinyl-benzilate"
      },
      {
        "id": 346,
        "title": "Tilmetamine",
        "slug": "tilmetamine"
      },
      {
        "id": 239,
        "title": "2C-N",
        "slug": "2c-n"
      },
      {
        "id": 515,
        "title": "25T-2-NBOMe",
        "slug": "25t-2-nbome"
      },
      {
        "id": 263,
        "title": "DOC",
        "slug": "doc"
      },
      {
        "id": 266,
        "title": "TMA",
        "slug": "tma"
      },
      {
        "id": 264,
        "title": "2C-F",
        "slug": "2c-f"
      },
      {
        "id": 351,
        "title": "2-Chloroephenidine",
        "slug": "2-chloroephenidine"
      },
      {
        "id": 368,
        "title": "3,4-MD-PCP",
        "slug": "3-4-md-pcp"
      },
      {
        "id": 49,
        "title": "ALEPH",
        "slug": "aleph"
      },
      {
        "id": 268,
        "title": "ALEPH-2",
        "slug": "aleph-2"
      },
      {
        "id": 138,
        "title": "AMT",
        "slug": "amt"
      },
      {
        "id": 273,
        "title": "2C-P",
        "slug": "2c-p"
      },
      {
        "id": 276,
        "title": "3-HO-PCP",
        "slug": "3-ho-pcp"
      },
      {
        "id": 281,
        "title": "2C-EF",
        "slug": "2c-ef"
      },
      {
        "id": 285,
        "title": "DMT",
        "slug": "dmt"
      },
      {
        "id": 289,
        "title": "O-PCE",
        "slug": "o-pce"
      },
      {
        "id": 290,
        "title": "DMXE",
        "slug": "dmxe"
      },
      {
        "id": 257,
        "title": "DOEF",
        "slug": "doef"
      },
      {
        "id": 292,
        "title": "25CN-NBOH",
        "slug": "25cn-nboh"
      },
      {
        "id": 293,
        "title": "HXE",
        "slug": "hxe"
      },
      {
        "id": 295,
        "title": "2C-D",
        "slug": "2c-d"
      },
      {
        "id": 311,
        "title": "Cannabis",
        "slug": "cannabis"
      },
      {
        "id": 156,
        "title": "4-Methylthioamphetamine",
        "slug": "4-methylthioamphetamine"
      },
      {
        "id": 321,
        "title": "2C-C",
        "slug": "2c-c"
      },
      {
        "id": 326,
        "title": "DPT",
        "slug": "dpt"
      },
      {
        "id": 329,
        "title": "4-HO-PiPT",
        "slug": "4-ho-pipt"
      },
      {
        "id": 508,
        "title": "4-MeO-MiPT",
        "slug": "4-meo-mipt"
      },
      {
        "id": 338,
        "title": "4-HO-McPT",
        "slug": "4-ho-mcpt"
      },
      {
        "id": 392,
        "title": "2C-T-21",
        "slug": "2c-t-21"
      },
      {
        "id": 182,
        "title": "Sernyl",
        "slug": "sernyl"
      },
      {
        "id": 44,
        "title": "Dextromethorphan",
        "slug": "dextromethorphan"
      },
      {
        "id": 62,
        "title": "MDA",
        "slug": "mda"
      },
      {
        "id": 353,
        "title": "Ephenidine",
        "slug": "ephenidine"
      },
      {
        "id": 359,
        "title": "3-HO-PCE",
        "slug": "3-ho-pce"
      },
      {
        "id": 371,
        "title": "5-MeO-DPT",
        "slug": "5-meo-dpt"
      },
      {
        "id": 375,
        "title": "1B-LSD",
        "slug": "1b-lsd"
      },
      {
        "id": 401,
        "title": "2C-iP",
        "slug": "2c-ip"
      },
      {
        "id": 409,
        "title": "Salvia",
        "slug": "salvia"
      },
      {
        "id": 412,
        "title": "AL-LAD",
        "slug": "al-lad"
      },
      {
        "id": 425,
        "title": "5-MeO-DiBF",
        "slug": "5-meo-dibf"
      },
      {
        "id": 460,
        "title": "Scopolamine",
        "slug": "scopolamine"
      },
      {
        "id": 485,
        "title": "LSZ",
        "slug": "lsz"
      },
      {
        "id": 424,
        "title": "2-Me-DMT",
        "slug": "2-me-dmt"
      },
      {
        "id": 507,
        "title": "25P-NBOMe",
        "slug": "25p-nbome"
      },
      {
        "id": 518,
        "title": "2C-T-4-NBOMe",
        "slug": "2c-t-4-nbome"
      },
      {
        "id": 519,
        "title": "2C-T-7-NBOMe",
        "slug": "2c-t-7-nbome"
      },
      {
        "id": 531,
        "title": "25H-NBOMe",
        "slug": "25h-nbome"
      },
      {
        "id": 526,
        "title": "25I-NBMD",
        "slug": "25i-nbmd"
      },
      {
        "id": 528,
        "title": "25I-NBF",
        "slug": "25i-nbf"
      },
      {
        "id": 529,
        "title": "25I-NBOH",
        "slug": "25i-nboh"
      },
      {
        "id": 534,
        "title": "25C-NB3OMe",
        "slug": "25c-nb3ome"
      },
      {
        "id": 538,
        "title": "2-MeO-Ketamine",
        "slug": "2-meo-ketamine"
      },
      {
        "id": 539,
        "title": "2-MeO-DMT",
        "slug": "2-meo-dmt"
      },
      {
        "id": 540,
        "title": "2C-T-7",
        "slug": "2c-t-7"
      },
      {
        "id": 543,
        "title": "2C-B-FLY-NBOMe",
        "slug": "2c-b-fly-nbome"
      },
      {
        "id": 552,
        "title": "DCK",
        "slug": "dck"
      },
      {
        "id": 560,
        "title": "2-TFMXP",
        "slug": "2-tfmxp"
      },
      {
        "id": 570,
        "title": "4F-MDMB-BINACA",
        "slug": "4f-mdmb-binaca"
      },
      {
        "id": 583,
        "title": "AM-694",
        "slug": "am-694"
      },
      {
        "id": 584,
        "title": "ADBICA",
        "slug": "adbica"
      },
      {
        "id": 589,
        "title": "AMB-CHMICA",
        "slug": "amb-chmica"
      },
      {
        "id": 590,
        "title": "AMB-FUBINACA",
        "slug": "amb-fubinaca"
      },
      {
        "id": 594,
        "title": "CBNA",
        "slug": "cbna"
      },
      {
        "id": 597,
        "title": "Bufotenin",
        "slug": "bufotenin"
      },
      {
        "id": 599,
        "title": "Atropine",
        "slug": "atropine"
      },
      {
        "id": 600,
        "title": "AM-1248",
        "slug": "am-1248"
      },
      {
        "id": 605,
        "title": "25T-NBOMe",
        "slug": "25t-nbome"
      },
      {
        "id": 607,
        "title": "ADB-PINACA",
        "slug": "adb-pinaca"
      },
      {
        "id": 608,
        "title": "ADB-PINACA isomer 2",
        "slug": "adb-pinaca-isomer-2"
      },
      {
        "id": 609,
        "title": "AM-2201",
        "slug": "am-2201"
      },
      {
        "id": 611,
        "title": "BDCK",
        "slug": "bdck"
      },
      {
        "id": 616,
        "title": "AKB-57",
        "slug": "akb-57"
      },
      {
        "id": 622,
        "title": "4-MXP",
        "slug": "4-mxp"
      }
    ],
    "markdown": "# Mescaline · #59\n\n-      \"a-typical hallucinogen\",\n\n# 5-MeO-DMT · #60\n\n-      \"a-typical hallucinogen\",\n\n# 4-HO-MET · #73\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# EA-3167 · #79\n\n-      \"a-typical hallucinogen\",\n\n# 25I-NBOMe · #82\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-AcO-DMT · #102\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Canket · #106\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# FXE · #107\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# MAL · #270\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-BZ · #514\n\n-      \"a-typical hallucinogen\",\n\n# DOM · #139\n\n-      \"a-typical hallucinogen\",\n\n# DOB · #280\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# PMA · #158\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DiPT · #181\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DXM Polistirex · #189\n\n-      \"a-typical hallucinogen\",\n\n# LSD · #191\n\n-      \"a-typical hallucinogen\",\n\n# Ibogaine · #196\n\n-      \"a-typical hallucinogen\",\n\n# Yopo · #199\n\n-      \"a-typical hallucinogen\",\n\n# Penis Envy · #200\n\n-      \"a-typical hallucinogen\",\n\n# Bromo-DragonFLY · #205\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Kratom · #206\n\n-      \"a-typical hallucinogen\",\n\n# Amanita Muscaria · #201\n\n-      \"a-typical hallucinogen\",\n\n# Ibotenic acid · #215\n\n-      \"gabaergic\",\n-      \"A-typical hallucinogen\"\n+      \"gabaergic\"\n\n# DOET · #222\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 3-Quinuclidinyl benzilate · #80\n\n-      \"a-typical hallucinogen\",\n\n# Tilmetamine · #346\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-N · #239\n\n-      \"a-typical hallucinogen\",\n\n# 25T-2-NBOMe · #515\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DOC · #263\n\n-      \"stimulant\",\n-      \"a-typical hallucinogen\"\n+      \"stimulant\"\n\n# TMA · #266\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-F · #264\n\n-      \"a-typical hallucinogen\",\n\n# 2-Chloroephenidine · #351\n\n-      \"a-typical hallucinogen\",\n\n# 3,4-MD-PCP · #368\n\n-      \"a-typical hallucinogen\",\n\n# ALEPH · #49\n\n-      \"stimulant\",\n-      \"a-typical hallucinogen\"\n+      \"stimulant\"\n\n# ALEPH-2 · #268\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# AMT · #138\n\n-      \"a-typical hallucinogen\",\n\n# 2C-P · #273\n\n-      \"a-typical hallucinogen\",\n\n# 3-HO-PCP · #276\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-EF · #281\n\n-      \"a-typical hallucinogen\",\n\n# DMT · #285\n\n-      \"a-typical hallucinogen\",\n\n# O-PCE · #289\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# DMXE · #290\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# DOEF · #257\n\n-      \"a-typical hallucinogen\",\n\n# 25CN-NBOH · #292\n\n-      \"a-typical hallucinogen\",\n\n# HXE · #293\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-D · #295\n\n-      \"a-typical hallucinogen\",\n\n# Cannabis · #311\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# 4-Methylthioamphetamine · #156\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-C · #321\n\n-      \"a-typical hallucinogen\",\n\n# DPT · #326\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-HO-PiPT · #329\n\n-      \"a-typical hallucinogen\",\n\n# 4-MeO-MiPT · #508\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4-HO-McPT · #338\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-21 · #392\n\n-      \"a-typical hallucinogen\",\n\n# Sernyl · #182\n\n-      \"a-typical hallucinogen\",\n\n# Dextromethorphan · #44\n\n-      \"a-typical hallucinogen\",\n\n# MDA · #62\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Ephenidine · #353\n\n-      \"a-typical hallucinogen\",\n\n# 3-HO-PCE · #359\n\n-      \"a-typical hallucinogen\",\n\n# 5-MeO-DPT · #371\n\n-      \"a-typical hallucinogen\",\n\n# 1B-LSD · #375\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-iP · #401\n\n-      \"a-typical hallucinogen\",\n\n# Salvia · #409\n\n-      \"A-typical hallucinogen\",\n\n# AL-LAD · #412\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 5-MeO-DiBF · #425\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# Scopolamine · #460\n\n-      \"deliriant\",\n-      \"a-typical hallucinogen\"\n+      \"deliriant\"\n\n# LSZ · #485\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2-Me-DMT · #424\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25P-NBOMe · #507\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-4-NBOMe · #518\n\n-      \"a-typical hallucinogen\",\n\n# 2C-T-7-NBOMe · #519\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25H-NBOMe · #531\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBMD · #526\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBF · #528\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25I-NBOH · #529\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 25C-NB3OMe · #534\n\n-      \"a-typical hallucinogen\",\n\n# 2-MeO-Ketamine · #538\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2-MeO-DMT · #539\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 2C-T-7 · #540\n\n-      \"a-typical hallucinogen\",\n\n# 2C-B-FLY-NBOMe · #543\n\n-      \"a-typical hallucinogen\",\n\n# DCK · #552\n\n-      \"a-typical hallucinogen\",\n\n# 2-TFMXP · #560\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# 4F-MDMB-BINACA · #570\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# AM-694 · #583\n\n-      \"a-typical hallucinogen\",\n\n# ADBICA · #584\n\n-      \"depressant\",\n-      \"a-typical hallucinogen\"\n+      \"depressant\"\n\n# AMB-CHMICA · #589\n\n-      \"a-typical hallucinogen\",\n\n# AMB-FUBINACA · #590\n\n-      \"a-typical hallucinogen\",\n\n# CBNA · #594\n\n-      \"nootropic\",\n-      \"a-typical hallucinogen\"\n+      \"nootropic\"\n\n# Bufotenin · #597\n\n-      \"a-typical hallucinogen\",\n\n# Atropine · #599\n\n-      \"deliriant\",\n-      \"a-typical hallucinogen\"\n+      \"deliriant\"\n\n# AM-1248 · #600\n\n-      \"a-typical hallucinogen\",\n\n# 25T-NBOMe · #605\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# ADB-PINACA · #607\n\n-      \"habit-forming\",\n-      \"a-typical hallucinogen\"\n+      \"habit-forming\"\n\n# ADB-PINACA isomer 2 · #608\n\n-      \"a-typical hallucinogen\",\n\n# AM-2201 · #609\n\n-      \"a-typical hallucinogen\",\n\n# BDCK · #611\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"\n\n# AKB-57 · #616\n\n-      \"a-typical hallucinogen\",\n\n# 4-MXP · #622\n\n-      \"research-chemical\",\n-      \"a-typical hallucinogen\"\n+      \"research-chemical\"",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-191133-9b6f5ac8",
    "createdAt": "2025-10-16T19:11:33.130Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:11:30"
    },
    "articles": [
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      },
      {
        "id": 321,
        "title": "2C-C",
        "slug": "2c-c"
      }
    ],
    "markdown": "# 2C-BZ · #514\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"a-typical hallucinogen\",\n\n# 2C-C · #321\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-          \"canonical_routes\": [\n-            \"insufflated\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"insufflated\"\n+          ]\n-      \"a-typical hallucinogen\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-191042-5c6a6d64",
    "createdAt": "2025-10-16T19:10:42.055Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:10:39"
    },
    "articles": [
      {
        "id": 514,
        "title": "2C-BZ",
        "slug": "2c-bz"
      }
    ],
    "markdown": "# 2C-BZ · #514\n\n-          \"canonical_routes\": [\n-            \"oral\"\n-          ],\n-          }\n+          },\n+          \"canonical_routes\": [\n+            \"oral\"\n+          ]\n-      \"a-typical hallucinogen\",",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-190938-8a5873a8",
    "createdAt": "2025-10-16T19:09:38.185Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 16/10/2025, 21:09:35"
    },
    "articles": [],
    "markdown": "No diff details were provided for this commit.",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251016-083502-09318c26",
    "createdAt": "2025-10-16T08:35:02.514Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/16/2025, 2:35:00 AM"
    },
    "articles": [
      {
        "id": 36,
        "title": "Trazodone",
        "slug": "trazodone"
      },
      {
        "id": 86,
        "title": "Tranylcypromine",
        "slug": "tranylcypromine"
      },
      {
        "id": 144,
        "title": "Phenelzine",
        "slug": "phenelzine"
      },
      {
        "id": 186,
        "title": "Vilazodone",
        "slug": "vilazodone"
      },
      {
        "id": 303,
        "title": "Ondansetron",
        "slug": "ondansetron"
      },
      {
        "id": 302,
        "title": "Moclobemide",
        "slug": "moclobemide"
      },
      {
        "id": 301,
        "title": "Quetiapine",
        "slug": "quetiapine"
      },
      {
        "id": 307,
        "title": "Tianeptine",
        "slug": "tianeptine"
      },
      {
        "id": 374,
        "title": "Lean",
        "slug": "lean"
      },
      {
        "id": 430,
        "title": "Olanzapine",
        "slug": "olanzapine"
      },
      {
        "id": 442,
        "title": "Clobenzorex",
        "slug": "clobenzorex"
      },
      {
        "id": 458,
        "title": "Chlorpheniramine",
        "slug": "chlorpheniramine"
      },
      {
        "id": 530,
        "title": "Ro5-4864",
        "slug": "ro5-4864"
      }
    ],
    "markdown": "# Trazodone · #36\n\n-    \"psychoactive_class\": \"Antidepressant (Serotonin Antagonist and Reuptake Inhibitor, SARI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Tranylcypromine · #86\n\n-    \"psychoactive_class\": \"Antidepressant (Monoamine Oxidase Inhibitor, MAOI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Phenelzine · #144\n\n-    \"psychoactive_class\": \"Antidepressant (Monoamine Oxidase Inhibitor, MAOI)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Vilazodone · #186\n\n-    \"psychoactive_class\": \"Antidepressant (Selective Serotonin Reuptake Inhibitor and 5-HT1A receptor partial agonist)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Ondansetron · #303\n\n-    \"psychoactive_class\": \"Antiemetic (not psychoactive in the traditional sense, but acts on the central nervous system to prevent nausea/vomiting)\",\n+    \"psychoactive_class\": \"Antiemetic\",\n\n# Moclobemide · #302\n\n-    \"psychoactive_class\": \"Antidepressant (Reversible MAO-A inhibitor)\",\n+    \"psychoactive_class\": \"Antidepressant\",\n\n# Quetiapine · #301\n\n-    \"psychoactive_class\": \"Atypical antipsychotic\",\n+    \"psychoactive_class\": \"Antipsychotic (atypical)\",\n\n# Tianeptine · #307\n\n-    \"psychoactive_class\": \"Full μ-opioid receptor agonist; atypical antidepressant\",\n+    \"psychoactive_class\": \"Full μ-opioid receptor agonist; Antidepressant (atypical)\",\n\n# Lean · #374\n\n-    \"psychoactive_class\": \"Opioid depressant; antihistamine sedative\",\n+    \"psychoactive_class\": \"Opioid depressant; Antihistamine; Sedative\",\n\n# Olanzapine · #430\n\n-    \"psychoactive_class\": \"Atypical antipsychotic (multi-receptor antagonist)\",\n+    \"psychoactive_class\": \"Antipsychotic (atypical)\",\n\n# Clobenzorex · #442\n\n-    \"psychoactive_class\": \"Catecholaminergic stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n+    \"psychoactive_class\": \"Stimulant; prodrug that yields d-amphetamine (~15 % conversion)\",\n\n# Chlorpheniramine · #458\n\n-    \"psychoactive_class\": \"Antihistamine (H1 receptor antagonist)\",\n+    \"psychoactive_class\": \"Antihistamine\",\n\n# Ro5-4864 · #530\n\n-    \"psychoactive_class\": \"atypical benzodiazepine; TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",\n+    \"psychoactive_class\": \"Benzodiazepine (atypical); TSPO (18 kDa translocator protein) agonist with weak or absent classical GABA_A activity\",",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251014-233456-d6536e79",
    "createdAt": "2025-10-14T23:34:56.256Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/14/2025, 5:34:54 PM"
    },
    "articles": [
      {
        "id": 294,
        "title": "Bromantane",
        "slug": "bromantane"
      }
    ],
    "markdown": "### Bromantane · #294\n\n- `drug_info.psychoactive_class`: \"Stimulant actoprotector; anxiolytic nootropic\" → \"Stimulant actoprotector; anxiolytic; nootropic\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251014-233158-373c6f71",
    "createdAt": "2025-10-14T23:31:58.069Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/14/2025, 5:31:55 PM"
    },
    "articles": [
      {
        "id": 152,
        "title": "Dimenhydrinate",
        "slug": "dimenhydrinate"
      },
      {
        "id": 396,
        "title": "Propranolol",
        "slug": "propranolol"
      },
      {
        "id": 417,
        "title": "Avizafone",
        "slug": "avizafone"
      }
    ],
    "markdown": "### Dimenhydrinate · #152\n\n- `drug_info.psychoactive_class`: \"Deliriant (anticholinergic); Antihistamine; Anti-emetic\" → \"Deliriant; Antihistamine; Anti-emetic\"\n\n### Propranolol · #396\n\n- `drug_info.psychoactive_class`: updated long text (98 characters; starts \"Not typically classified as psychoactive; Antihypertensive; antiarrhy...\") → text (\"Not typically classified as psychoactive; Antihypertensive; antiarrhythmic; anxiolytic\")\n\n### Avizafone · #417\n\n- `drug_info.psychoactive_class`: \"Sedative-hypnotic; anxiolytic (benzodiazepine)\" → \"Sedative-hypnotic; anxiolytic\"",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251013-212828-39bd2cd6",
    "createdAt": "2025-10-13T21:28:28.668Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 13/10/2025, 23:28:26"
    },
    "articles": [
      {
        "id": 595,
        "title": "1cP-MiPLA",
        "slug": "1cp-mipla"
      }
    ],
    "markdown": "### 1cP-MiPLA · #595\n\n- `drug_info.dosages.routes_of_administration[0].dose_ranges.heavy`: \"300 µg +\" → \"300 µg +\"\n- `drug_info.dosages.routes_of_administration[1].dose_ranges.heavy`: \"250 µg +\" → \"250 µg +\"\n- `drug_info.categories[1]`: \"a-typical hallucinogen\" → \"research-chemical\"\n- `drug_info.categories[2]`: removed text (\"research-chemical\")",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251013-212356-370466a5",
    "createdAt": "2025-10-13T21:23:56.596Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 13/10/2025, 23:23:53"
    },
    "articles": [],
    "markdown": "No changelog details were provided for this commit.",
    "submittedBy": "WITCHY"
  },
  {
    "id": "20251013-210154-43d82145",
    "createdAt": "2025-10-13T21:01:54.147Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/13/2025, 3:01:52 PM"
    },
    "articles": [
      {
        "id": 33,
        "title": "3-MeO-PCP",
        "slug": "3-meo-pcp"
      }
    ],
    "markdown": "### 3-MeO-PCP · #33\n\n- `drug_info.alternative_name`: added text (\"3-Methoxyphencyclidine\")",
    "submittedBy": "JOSIE"
  },
  {
    "id": "20251012-120815-ffa8a8d5",
    "createdAt": "2025-10-12T12:08:15.759Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/12/2025, 6:08:14 AM"
    },
    "articles": [
      {
        "id": 510,
        "title": "3-Cl-PCP",
        "slug": "3-cl-pcp"
      }
    ],
    "markdown": "### 3-Cl-PCP · #510\n\n- `drug_info.categories[2]`: removed (was `a-typical hallucinogen`)"
  },
  {
    "id": "20251012-120542-f6e605f4",
    "createdAt": "2025-10-12T12:05:42.088Z",
    "commit": {
      "sha": "",
      "url": "",
      "message": "Dev editor update - 10/12/2025, 6:05:40 AM"
    },
    "articles": [
      {
        "id": 389,
        "title": "3-MeO-PCMo",
        "slug": "3-meo-pcmo"
      }
    ],
    "markdown": "### 3-MeO-PCMo · #389\n\n- `content`: `# 3-MeO-PCMo\n## Arylcyclohexylamine (morpholine subgroup) | Dissociative NMDA-receptor antagonist with mild monoaminergic activity\n      \nPotency is roughly 1/10 of 3-MeO-PCP but still active in double-digit milligram range; weigh on 0.001 g scale and perform 1-3 mg allergy test. Virtually no clinical history: all human data are anecdotal. Reports of confusion, mania and prolonged delirium at heavy doses. Limited reagent-test data; use full panel to rule out NBOMe / opioid adulterants. Crystal often hygroscopic – store in airtight, light-protected container with desiccant.` → ``"
  }
]